A lawsuit challenges the FDA's decision to remove semaglutide from the shortage list, alleging it was arbitrary and harms ...
Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...
Novo Nordisk A/S’s weight-loss and diabetes drugs are no longer in short supply, US regulators said, a decision that’s ...
The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...
Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug ...
Makers of copycat weight-loss drugs and digital health companies that sell them are bracing for upheaval now that the Food ...
The FDA has now resolved the shortages of Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...
Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration ...
Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to ...
Delivery apps are allowing Chinese citizens to get their hands on the popular weight-loss and diabetes drugs at the touch of ...